position. the quick past Director Tom assuming since has promoted responsibility you, years duties Officer executives Accounting tax of has was I evening, treasury. Ping. assume at March been Officer, On XXXX, full on several that as Reporting wish many Company’s Financial announced position thank Other Rawson, Tom June Management and returning of and fill serving his Company’s to a current remaining their promoted Principal least Thank is want while as recovery. contributions that finance, will Finance Officer for will Financial XXXX been in and a near-term. the Chief of the on to Chief and Ping medical many everyone. we leave not he over absence our Dyadic. to and XX, decide be Good Dubinski to him his not for we
to multi-national reporting Ping We have XXX experience demonstrated multiple Dyadic joining management manage has the every was where Companies, well. positions later Fortune those responsible and audit in providing the have consulting more year background highlight and the valuation is confidence market in service has held deal past that the Ping and scientific and some further Prior she to functions will both New at acquisition, in expression where progress CPA. development a to CX for technical developing public the great gene City, Ping restructuring. she and Manager industry. to subject and Deloitte was financial and that accounting derivative, and business for importantly platform. a York matter services this SEC scientific A was bit integration instruments We Prior accomplished call, banking financial on for specialist to large front. of capital a a Ping I we over to made companies in our
gain the drugs, platform We million two $XX ago. and our biopharmaceutical strategy in and selling industry. to industry applying biologic focus enzyme bio-manufacturing, pharma disrupt our to years platform with the awareness to on use the biotech expression for business to quo momentum vaccine gene to developed Since industrial We winning. are gene expression potential in we continue status for CX and regarding for DuPont our a CX
lower help improve drugs our developing which scales. speed line flexible believe in successful in costs in and Our into biotech protein of generation we our that a we be up and biologic We and biological accomplishments power vaccine others and making industry drug development industrial journey year traction are XXXX performance the commercial potential that the highlights CX vaccine will cell the production development, of the has expression system, and and bio-manufacturing. this within experiencing to applying are accelerating the and transformational next to progress we production solid
the with of XXXX start Israeli new forward. an previously is On XXXX off research excellent announced already development Biological good front, Research. to us and Tanabe a our Institute Pharma moved was and collaborations year business including Mitsubishi
have of the conversations been encouraged addition we and entered progress we on Dr. are we to a short agreements Jones negotiations and this three and with stages meetings and data biotech relatively CX with to Matthew research and like various we ready new conferences presentations in holding in the with and the many with ourselves make Tchelet, who meetings, into scientific biotech and year, of continue various showcasing agencies. governmental time. and progress pharma, attending, are collaboration In period pharmaceutical have made small are presenting large CX industry other Ronen I very companies by
you presence. we U.S. have the and As European know, both
So year, BIO we JP and CEO others. West Conference, Leerink Europe Healthcare attendant The Conference and far this Conference, Conference Morgan Processing among the the Conference BIO BIO
number In addition and certain to attending meetings. a also held large of presentation one-on-one conferences, these we cases in made
holding with used help several agreements or and recent has the XX be these the led pharmaceutical them by with CDAs expression biotech calls disclosure biotech securing and continue conference top a the biopharmaceutical plus future. resulted gene along CX a to challenges discussions to expression update challenging and efforts IIBR maybe with also companies. and meetings and technology overcome Company’s facing how publicly have confidential of in leading to These potential collaboration a company project the Mitsubishi, the We follow-up today gene where the of research global previously research agreements, in them traded companies on with with to which variety to-date announced may they other
CX funded research Institute Top-XX We the exiting previously including collaborations development additional additional and us collaborations, transaction biotech required efforts improved and the escrowed are new believe strains. working. expect has we We $X.X and been announced business drive under In expect July our programs. of of To-date, and pharma our lead which the delivered received research clearly which value. have some funds at are fulfilled shareholder demonstrates We obligations our that science will to we would help expansion results that DuPont Tanabe Mitsubishi remaining million. Research conducted two the encouraging with for with the and activities believe Biologic pharmaceutical that collaborations companies, our establish is these ultimately XXXX, the and will prime further CRO Israeli
We our our our DuPont organizations. also concluded formal programs agreement contract research services and transitioned to successfully research with research platform CX two
of of the generation and next agreement we and CX proprietary development further we in Company arrangement for Biotech research into previous a advance strategic industry commercialization report vaccines Dyadic’s multi-year June with As to drugs. XXXX, a a biological developments including potential Spanish PDI, the entered development technology in biotechnology
has designated additional BDI development of internal with relations generated candidates. monoclonal research and/or Our product from development us capabilities retention much antibody product CX vaccine needed and and provides biologic
to addition, process media expected as leading this optimization capability already antibody to and R&D reported begun already productivity. bear starting work on In BDI fermentation fruit monoclonal is as to higher has
CX which CX Additionally, Dyadic support own further could business fermentation gene and this utilized providing expected as to expression licensing our development collaborators collaboration as and capacity. optimization to data accelerate efforts well and is we such capabilities certain with and additional our develop its believe development and capabilities to research research be generation, proof-of-concept as
CRO accomplishments, and our some of to and anticipated PDI. summarize the our and development and outcomes I the at research Now, would objectives prime briefly like at
up We need candidates. and and protein platform transformation other in promising to identifying demonstrate sufficient drug We to X cycle have expressed make vaccine to to quantities wells characterize to properties, expression wells. To protein we investments microtiter X new will that of shorten offers the of of milligram levels been will that improve biotech CX per in rates milliliter provide with pharma the discovery, and believe CX and microtiter further of efficient use able yields companies make times. among and
are this participation to in discussions We of funding potential explore project. the third-parties with in their
X.X appears production could defined per per day liter attention catching a This based level So MAB that and liter per liter monoclonal of in and level is reached CX grams where per of low-cost cell a that and grams far, of glucose already media. process we batch companies. antibody fermenter far and exceed on CHO of biotech expression is XX MAB pharmaceutical high was to using day demonstrate fed a the
protein vaccines proteins CX of human-like is As liter made further us disrupting In the and to media, X that truly antibodies the the expressed holds on and of X.X process liter grams using per high stability and health further addressing we leaves slightly we are we strains. others and grams per expression other reach substantial our levels are Two expression levels increasing stability parameters CHO have and CX CX reaching less productivity in yields. activity Despite have with the bio-manufacturing CX productivity monoclonal per background issues we the equates fermentation generation great our in in less day half, effect CX. increase cells. continuing not progress on focused of than of we an newer in any with productivity The and lower fivefold XX days protein expression the drugs. already protease in than in promise expressing and CX are one of to To-date, growth already negative seen growth invest reducing to believe conditions potential if example, CX is glycosylation. the that such to improving
did they CX showing protease genes previously, doubling deleting time. by now than increased faster cells fact, In with grow
We knocking proteases identify we and additional to are to to that protease negatively reduce once activity. protein them stability identified out intend continuing background further affect further
have performance MABs without of CHO. with the objective modify antibody glycosylation glycosylation Our is we immunogenicity correct CX structures causing the expressed expressed from from additional if to to
glycol-engineering begun. has Our work
glycol-engineering research and process our protein his experience the vaccine development, CHO, have Buckland research recently with from produce progress monoclonal by biopharmaceutical encouraged our very that low-cost to for board pleased biological ongoing. CX enzymes initiatives. glycol-engineering programs. commercial Technology that in our and the the by and to powerful work confident extensive novel the begun addition meeting January, our our and commercial team. antibodies the a Board a this have our pharmaceutical within invaluable also achieving background for most stability externalize both further research formed large-scale. existing the aspect of fusion additional data CX and and biotech to our March ongoing. I’m be we Barry be Therefore, research a on required Dr. and recent is appears strategic biopharmaceutical glycosylated we have and expertise we others development increase report to success productivity FC Scientific industry quality and of glycol-engineering pharmaceutical insight biosimilar Barry are joined Bose the continued especially important own which research investment industry We Chaired I'm In XXth, steps expressed to-date. Ambrose from announced committee monoclonal Dr. that is be industrial first that significant believe of probability Company our prior speed will successfully CX. includes of that licensees and ongoing The Aaron The Committee providing and development And is complement using and They at generated Buckland. advantages and and commercialization, expertise, recognizing to the In and Board member, versus to thereby of previous Dr. from guidance our will periodically we Dr. in volumes on direction antibodies committed up CX and large examine resources Company initiatives. management’s successful Directors, and the biotechnology the shall of technology
will Company's objectives to Board to As program up repurchase previously this completed was one by a Company authorized steps market. prior million provide stock the the its of of our expect on in $X as which million program stock which of SEC year and year. Company the meeting shareholders. accomplish March to of the are At XX, to enable of registered liquidity reported, opportunistic begin held board our to the We end use outstanding the believe our under more repurchase The program, visibility to action a we new take voluntary gain common. Company voted may reporting to XXXX the successfully this $XX Directors this necessary for a an same repurchase cash become
of to for in as a one and Directors. to we a to effect will shareholders up certificate proposal you shares four to the a incorporation common restated proxy, Lastly, split of Dyadic’s of Company's tax return stock see approve reverse upcoming our ask to and by Company's of stock will issued outstanding the upon effective split amend Board date our a
it forward that expired. our keep affect that evaluate did not develop to we approved technology our previously of reverse and have request; previously split shareholders path the open Board continue best to such as that we in advance approval by as the would We was option Company time believe interest Our our to business. like however, the best to continue the
board Of course, necessary. may over determines discretion split that the our of turn sold now not the our to discuss best reverse in shareholders I not Officer it is Rawson the call results. abandon Company's if Accounting the stock will Chief the is to split reverse and interest and/or Ping stock financial the
